TY - JOUR
T1 - Serum osteopontin levels are upregulated and predict disability after an ischaemic stroke
AU - Carbone, Federico
AU - Vuilleumier, Nicolas
AU - Burger, Fabienne
AU - Roversi, Gloria
AU - Tamborino, Carmine
AU - Casetta, Ilaria
AU - Seraceni, Silva
AU - Trentini, Alessandro
AU - Padroni, Marina
AU - Dallegri, Franco
AU - Mach, François
AU - Fainardi, Enrico
AU - Montecucco, Fabrizio
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Background: After an acute ischaemic stroke (AIS), several inflammatory biomarkers have been investigated, but their predictive role on functional recovery remains to be validated. Here, we investigated the prognostic relevance of biomarkers related to atherosclerotic plaque calcification, such as osteopontin (OPN), osteoprotegerin (OPG) and the receptor activator of nuclear factor kappa-B ligand (RANKL) in a cohort of patients with AIS (n = 90) during 90-day follow-up. Materials and methods: Radiological and clinical examinations as well as blood sampling were performed at admission and at days 1, 7 and 90 from the event. Validated scores [such as modified Rankin scale (mRS) and the National Institutes of Health Stroke Scale (NIHSS)] were used to assess poststroke outcome. Serum levels of OPN, OPG and RANKL were measured by colorimetric enzyme-linked immunosorbent assay (ELISA). Results: When compared to the admission, OPN serum levels increased at day 7. Serum OPN levels at this time point were positively correlated with both ischaemic lesion volume and NIHSS at days 7 and 90. A cut-off of 30·53 ng/mL was identified for serum OPN by receiver operating characteristic (ROC) curve analysis. Adjusted logistic regression showed that serum OPN levels at day 7 predicted worse mRS at day 90 [OR 4·13 (95% CI 1·64-10·36); P = 0·002] and NIHSS [1·49 (95% CI 1·16-1·99); P = 0·007], independently of age, gender, hypertension and thrombolysis. Conclusions: Serum levels of OPN, but not OPG and RANKL, peaked at day 7 after AIS and predicted worse neurological scores. Therefore, OPN might have a pathophysiological and clinical relevance after AIS.
AB - Background: After an acute ischaemic stroke (AIS), several inflammatory biomarkers have been investigated, but their predictive role on functional recovery remains to be validated. Here, we investigated the prognostic relevance of biomarkers related to atherosclerotic plaque calcification, such as osteopontin (OPN), osteoprotegerin (OPG) and the receptor activator of nuclear factor kappa-B ligand (RANKL) in a cohort of patients with AIS (n = 90) during 90-day follow-up. Materials and methods: Radiological and clinical examinations as well as blood sampling were performed at admission and at days 1, 7 and 90 from the event. Validated scores [such as modified Rankin scale (mRS) and the National Institutes of Health Stroke Scale (NIHSS)] were used to assess poststroke outcome. Serum levels of OPN, OPG and RANKL were measured by colorimetric enzyme-linked immunosorbent assay (ELISA). Results: When compared to the admission, OPN serum levels increased at day 7. Serum OPN levels at this time point were positively correlated with both ischaemic lesion volume and NIHSS at days 7 and 90. A cut-off of 30·53 ng/mL was identified for serum OPN by receiver operating characteristic (ROC) curve analysis. Adjusted logistic regression showed that serum OPN levels at day 7 predicted worse mRS at day 90 [OR 4·13 (95% CI 1·64-10·36); P = 0·002] and NIHSS [1·49 (95% CI 1·16-1·99); P = 0·007], independently of age, gender, hypertension and thrombolysis. Conclusions: Serum levels of OPN, but not OPG and RANKL, peaked at day 7 after AIS and predicted worse neurological scores. Therefore, OPN might have a pathophysiological and clinical relevance after AIS.
KW - Ischaemic stroke
KW - Osteopontin
KW - Osteoprotegerin
KW - Receptor activator of nuclear factor kappa-B ligand
UR - http://www.scopus.com/inward/record.url?scp=84929512076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84929512076&partnerID=8YFLogxK
U2 - 10.1111/eci.12446
DO - 10.1111/eci.12446
M3 - Article
C2 - 25845543
AN - SCOPUS:84929512076
VL - 45
SP - 579
EP - 586
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
SN - 0014-2972
IS - 6
ER -